KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials (2016 - 2022)

TherapeuticsMD's Raw Materials history spans 11 years, with the latest figure at $1.9 million for Q3 2022.

  • For Q3 2022, Raw Materials fell 44.19% year-over-year to $1.9 million; the TTM value through Sep 2022 reached $1.9 million, down 44.19%, while the annual FY2021 figure was $3.0 million, 18.84% down from the prior year.
  • Raw Materials reached $1.9 million in Q3 2022 per TXMD's latest filing, up from $434000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $5.7 million in Q4 2019 to a low of $19400.0 in Q4 2018.
  • Average Raw Materials over 5 years is $3.0 million, with a median of $3.6 million recorded in 2020.
  • Peak YoY movement for Raw Materials: surged 29290.45% in 2019, then crashed 90.43% in 2022.
  • A 5-year view of Raw Materials shows it stood at $19400.0 in 2018, then soared by 29290.45% to $5.7 million in 2019, then plummeted by 34.27% to $3.7 million in 2020, then dropped by 18.84% to $3.0 million in 2021, then plummeted by 36.03% to $1.9 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Raw Materials are $1.9 million (Q3 2022), $434000.0 (Q2 2022), and $4.4 million (Q1 2022).